https://www.bioworld.com/rss en-us While biomedical resources in the form of specialized tools, hundreds of thousands of published papers and huge repositories of ‘omics, health records and other data, are growing exponentially, discovery is getting slower and more expensive. That is the perspective from which scientists at Stanford University approached the development of their artificial intelligence (AI) research assistant Biomni. http://www.bioworld.com/articles/732620 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732620-ai-co-scientist-performs-biomedical-research-at-expert-level-in-less-time Data flow concept Suzhou Puhe Biopharma Co. Ltd. has patented new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732559 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732559-suzhou-puhe-biopharma-discovers-new-kras-mutant-inhibitors Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of neurodegeneration and inflammatory disorders. http://www.bioworld.com/articles/732558 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732558-nrf2-activators-reported-in-vailima-peninsula-patent Shanghai Peptidstar Therapeutics Ltd. has divulged new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease. http://www.bioworld.com/articles/732557 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732557-shanghai-peptidstar-therapeutics-synthesizes-new-il-23r-antagonists K2 Medicines (Nanjing) Co. Ltd. has disclosed new epidermal growth factor receptor (EGFR; ERBB1; HER1) mutant inhibitors potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732556 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732556-k2-medicines-patents-egfr-mutant-inhibitors Anew Therapeutics Pte Ltd. has discovered new interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors reported be useful for the treatment of Crohn’s disease, type 1 diabetes, dry eye and more. http://www.bioworld.com/articles/732555 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732555-anew-therapeutics-identifies-new-il-17a-il-17ra-interaction-inhibitors Thioredoxin reductase 1 (TXNRD1) is a key component of the thioredoxin antioxidant system that helps maintain cellular redox homeostasis and regulates critical cellular processes such as proliferation, apoptosis and immune responses. A team of researchers at Central South University systematically investigated TXNRD1 expression and function in psoriatic keratinocytes using gene expression datasets, clinical samples and in vitro and in vivo models. http://www.bioworld.com/articles/732552 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732552-txnrd1-links-keratinocyte-hyperproliferation-and-inflammation-in-psoriasis-emerging-as-a-target Doctor holding illustration of cross section of skin Researchers from Chongqing Medical University have presented data regarding an antiviral compound, KM-10411, derived from a FUBP1 inhibitor (FUBP1-IN-1), as a potential approach to treat hepatitis B virus (HBV) infections. http://www.bioworld.com/articles/732551 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732551-km-10411-shows-anti-hbv-effects-dependent-on-dusp5 Hepatitis B virus Rani Therapeutics Holding Inc. has entered into a research and development collaboration with Pegbio Co. Ltd. to explore the delivery of multiple candidates from Pegbio’s obesity and metabolic disease pipeline using Rani’s proprietary Ranipill platform. http://www.bioworld.com/articles/732550 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732550-rani-collaborates-with-pegbio-on-oral-drug-delivery-in-obesity Illustration of pill being analyzed Apertura Gene Therapy has entered into a cooperative research and development agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Human Genome Research Institute. http://www.bioworld.com/articles/732549 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732549-apertura-gene-therapy-enters-crada-for-niemann-pick-disease Researchers from Flavii Therapeutics SL and collaborators presented preclinical data on FLAV-27, a G9a inhibitor designed to target G9a-mediated epigenetic dysregulation. http://www.bioworld.com/articles/732548 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732548-flav-27-improves-asd-like-behaviors-in-btbr-mice Mindbeam AI has leveraged generative AI to accelerate the discovery of novel pain therapeutics predicted to have improved liver safety compared to acetaminophen. http://www.bioworld.com/articles/732547 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732547-mindbeam-ai-discovers-trpv1-modulators-for-pain Microscope with beakers and flasks Fate Therapeutics Inc. has obtained IND clearance from the FDA for FT-839, the company’s next-generation, off-the-shelf CAR T-cell product candidate targeting CD19 and CD38 for autoimmune diseases. http://www.bioworld.com/articles/732546 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732546-fate-therapeutics-ft-839-gains-ind-clearance Illustration of CAR T cells Atsena Therapeutics Inc. has selected a lead clinical candidate for ATSN-401, a gene therapy for Stargardt disease. ATSN-401 is now advancing in IND-enabling studies. http://www.bioworld.com/articles/732545 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732545-atsena-selects-atsn-401-clinical-candidate-for-stargardt-disease Art concept for gene therapy The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has announced the teams for the THRIVE (Treating Hereditary Rare diseases with In Vivo prEcision genetic medicines) program. With a commitment of up to $160 million over 5 years, THRIVE aims to accelerate solutions for rare genetic pediatric diseases across multiple technological approaches, clinical trial designs and deployment models. http://www.bioworld.com/articles/732544 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732544-arpa-h-program-supports-advances-for-rare-genetic-diseases Apolin Bio Ltd. and Shanghai Viva Dancheng Entrepreneurship Incubator Management Ltd. have detailed polycyclic compounds acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors that are potentially useful for the treatment of cardiovascular disorders. http://www.bioworld.com/articles/732513 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732513-apolin-bio-and-viva-biotech-present-new-apoa-apob-interaction-inhibitors Nuvalent Inc. has described RAC-α serine/threonine-protein kinase (AKT1; PKBα) E17K mutant inhibitors reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732512 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732512-nuvalent-discloses-new-akt1-inhibitors U&S Bio Co. Ltd. has divulged H+/K+-ATPase inhibitors with improved stability found to be potentially useful for the treatment of gastrointestinal disorders, cancer, Helicobacter pylori infection, sialorrhea, asthma and airways obstruction, among others. Helicobacter pylori infection, sialorrhea, asthma and airways obstruction, among others.]]> http://www.bioworld.com/articles/732511 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732511-u-and-s-bio-identifies-new-h-k-atpase-inhibitors Prelude Therapeutics Inc. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase (CRBN)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety that are potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732510 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732510-prelude-therapeutics-patents-new-kat6a-targeting-protacs Promomed Rus LLC has identified Janus kinase (JAK) inhibitors reported to be useful for the treatment of alopecia, atopic dermatitis, juvenile arthritis, rheumatoid arthritis, systemic lupus erythematosus and psoriatic arthritis. http://www.bioworld.com/articles/732509 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732509-promomed-rus-discovers-new-jak-inhibitors Acute lung injury (ALI) is an inflammatory pulmonary disease mainly caused by infection. It can progress to the life-threatening condition acute respiratory distress syndrome (ARDS). ALI/ARDS account for a high mortality rate of about 40%. Elucidating the mechanisms behind ALI/ARDS is crucial for developing new therapeutics. http://www.bioworld.com/articles/732504 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732504-usp43-targeting-protects-against-acute-lung-injury Lungs wireframe illustration Researchers from Stony Brook University Renaissance School of Medicine recently disclosed the design and development of a novel, multitargeted miRNA approach based on a gemcitabine-modified microRNA (miR)-129 mimic (Gem-miR-129) to overcome resistance to EGFR inhibitors. http://www.bioworld.com/articles/732503 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732503-gemcitabine-modified-dual-action-mir-129-mimic-shows-activity-in-nsclc 3D illustration and light micrograph of lung cancer. Niagen Bioscience Inc. has announced the initiation of a program targeting accelerated aging and rare genetic diseases, with the development by subsidiary NAD Pharmaceuticals Corp. of its first drug candidate, NB-4168. http://www.bioworld.com/articles/732502 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732502-niagen-bioscience-unveils-nb-4168-for-ataxia-telangiectasia Illustration of enzyme wrapped around double helix Researchers at the University of South Florida have focused on the demyelination hallmark of traumatic brain injury (TBI) and have tested a liver X receptor (LXR) agonist, GW-3965, for the potential treatment of it. Activation of LXRs is known to support oligodendrocyte maturation, increase myelin gene expression and promote remyelination. http://www.bioworld.com/articles/732501 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732501-lxr-agonist-gw-3965-improves-outcomes-in-tbi-model Digital brain and silhouette Rybodyn Inc. has been awarded $1.3 million from the U.S. Department of War to advance preclinical development of two novel antibody-based therapies for lung cancer. http://www.bioworld.com/articles/732500 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732500-grant-supports-rybodyns-antibody-therapies-for-lung-cancer Lung cancer illustration Urogen Pharma Ltd. has obtained IND approval from the FDA for UGN-501, a next-generation investigational oncolytic virus. A phase I study evaluating intravesical administration of UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC) is expected to begin in the fourth quarter. http://www.bioworld.com/articles/732499 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732499-urogens-ugn-501-gains-ind-clearance-for-bladder-cancer Art concept for bladder A selection of top research news from April through June 2026. http://www.bioworld.com/articles/732498 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732498-best-of-bioworld-science-q2 Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development, according to presentations at the FENS Forum 2026. http://www.bioworld.com/articles/732497 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732497-fens-2026-next-gen-biologics-take-on-brain-disease Silhouette with keyhole A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC). http://www.bioworld.com/articles/732495 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732495-beijing-mabworks-biotech-discloses-new-dll3-targeting-adcs Beijing Jingwei-Yankang Biomedical Co. Ltd. has reported new phenyl-substituted heterocyclic compounds acting as retinol-binding protein 4 (RBP4) inhibitors with potential in the treatment of age-related macular degeneration (AMD). http://www.bioworld.com/articles/732494 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732494-beijing-jingwei-yankang-biomedical-divulges-new-rbp4-inhibitors